Kidney TransplantationArchives
COVID-19 boosters restore virus-specific immune responses in kidney transplant recipients unresponsive to primary vaccination
Kidney Transplantation 8 min.
Due to the lifelong immunosuppressive therapies required to prevent transplant rejection, KTRs exhibit impaired immune responses to vaccination against pathogens such as hepatitis B, influenza virus, and Streptococcus pneumoniae1. The implications of this impaired vaccine responsiveness became...
Prehabilitation interventions to support the postoperative recovery of adult kidney transplant candidates: a scoping review
Kidney Transplantation 5 min.
Approximately four million Canadians are affected by chronic kidney disease (CKD) [1]. CKD is a gradual loss of kidney function over time which can progress to end stage kidney disease (ESKD), a condition that affects about 48,375 Canadians [2]. While there is no cure for kidney failure, renal replacement...
Evaluation of everolimus pharmacokinetic monitoring based on trough concentration and area under the blood concentration time curve in kidney transplantation
Kidney Transplantation 4 min.
Everolimus (EVR) is a proliferation-signal inhibitor developed as an immunosuppressive therapy following solid-organ transplantation. Among kidney transplant recipients (KTRs), calcineurin inhibitor (CNI)-associated nephrotoxicity remains a major barrier to long-term graft survival. EVR has emerged as...
Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from Israel
Kidney Transplantation 1 min.
Safety is a concern for solid-organ transplant (SOT) recipients with systemic inflammatory diseases (SIDs) treated with biologic therapy. This study evaluated the safety of biologic therapy in SOT recipients with SIDs. Methods: This retrospective study between 2000 and 2024 included 20 biologic-treated...
